DexCom, Inc. (DXCM)
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.
3 Stocks Doing the Heavy Lifting in Healthcare's Rebound
Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were stolen during disposal and resold.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, according to study results.
Here's Why You Should Retain DexCom Stock in Your Portfolio
DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dexcom warns patients as stolen glucose sensors hit the market
Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were instead stolen and sold, prompting the company to warn users not to use products from two affected lots.
DexCom Might Finally Be Cheap Enough
DexCom is now rated a 'Buy' as improved fundamentals and a 15% lower stock price present a more attractive entry. Q1/26 results showed 15% revenue growth, and 90.9% operating income growth and raised 2026 guidance for both revenue and margins. Key growth drivers include international expansion, increased U.S. coverage for type 2 diabetics, and a $1B share buyback in 2026.
